ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.64
0.00%
US Tech 100
20,355.20
0.61%
S&P 500
5,969.34
0.35%
US Dollar vs CAD
1.39678
-0.09%
Bitcoin
98,238.36
0.20%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Mural Oncology PLC (MURA) Share Price

Mural Oncology PLC

Mural Oncology PLC (MURA)

NASDAQ
3.35
-0.02
(-0.59%)
Closed November 22 3:00PM
Delayed by 15 minutes
3.77
0.42
( 12.54% )
Pre Market: 5:31AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
3.77
Bid
3.73
Ask
3.77
Volume
38,675
0.00 Day's Range 0.00
2.88 52 Week Range 6.2499
Previous Close
3.35
Open
-
Last Trade
1
@
3.77
Last Trade Time
05:26:04
Average Volume (3m)
84,060
Financial Volume
-
VWAP
-

Ask ADVFN Intelligence (AI)

MURA Latest News

More News

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily...

November 20 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

November 19 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

November 13 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 13 2024
Edgar (US Regulatory)

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2...

November 13 2024
GlobeNewswire Inc.

Mural Oncology to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

November 11 2024
GlobeNewswire Inc.

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and...

November 07 2024
GlobeNewswire Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

November 04 2024
GlobeNewswire Inc.

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

October 07 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.349.912536443153.433.533.26736943.39725632CS
40.267.407407407413.513.693.25536473.46117403CS
120.52163.253.922.99840603.35570951CS
260.010.2659574468093.763.922.881313033.28104789CS
520.164.432132963993.616.24992.882497604.07216774CS
156-12.92-77.411623726816.69172.882828834.0958517CS
260-12.92-77.411623726816.69172.882828834.0958517CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QMMMQMMM Holdings Limited
US$ 1.375
(83.36%)
11.59M
RGTIRigetti Computing Inc
US$ 2.555
(46.84%)
25.79M
PDYNPalladyne AI Corporation
US$ 6.18
(34.35%)
2.26M
QMCOQuantum Corporation
US$ 12.03
(31.76%)
924.66k
PAHCPhibro Animal Health Corporation
US$ 30.54
(28.64%)
1
AKTSAkoustis Technologies Inc
US$ 0.0695
(-30.91%)
4.7M
ONCTOncternal Therapeutics Inc
US$ 0.7899
(-30.71%)
13.28k
HSTMHealthStream Inc
US$ 25.12
(-21.96%)
6
ACTUActuate Therapeutics Inc
US$ 7.11
(-20.82%)
1
SRDXSurModics Inc
US$ 31.27
(-20.49%)
1
RGTIRigetti Computing Inc
US$ 2.555
(46.84%)
25.79M
QMMMQMMM Holdings Limited
US$ 1.375
(83.36%)
11.59M
ELABElevai Labs Inc
US$ 0.0176
(-12.44%)
9.24M
AKTSAkoustis Technologies Inc
US$ 0.0695
(-30.91%)
4.7M
QUBTQuantum Computing Inc
US$ 7.04
(15.41%)
3.97M

Discussion

View Full Feed
TrendTrade2016 TrendTrade2016 3 minutes ago
WLDa monster Gapper. Market is on fire
WLDS
WeTheMarket WeTheMarket 3 minutes ago
Mission Hydrogen webinar "Hydrogen EPC - Real life experience", Wed. Nov 27, 10 am ET.
Link to register https://event.webinarjam.com/register/963/44lyrhxq7

What You Will Learn In The Webinar

One of the most pressing challenges in the hydrogen industry is bridging
FCEL
WeTheMarket WeTheMarket 4 minutes ago
Mission Hydrogen webinar "Hydrogen EPC - Real life experience", Wed. Nov 27, 10 am ET.
Link to register https://event.webinarjam.com/register/963/44lyrhxq7

What You Will Learn In The Webinar

One of the most pressing challenges in the hydrogen industry is bridging
tw0122 tw0122 4 minutes ago
Singapore low floater RS complete $1.86
XTKG
JOoa0ky JOoa0ky 4 minutes ago
$3.50 Wall
FNMA
WeTheMarket WeTheMarket 5 minutes ago
Mission Hydrogen webinar "Hydrogen EPC - Real life experience", Wed. Nov 27, 10 am ET.
Link to register https://event.webinarjam.com/register/963/44lyrhxq7

What You Will Learn In The Webinar

One of the most pressing challenges in the hydrogen industry is bridging
PLUG
budfoxfun budfoxfun 6 minutes ago
CEO of The Sustainable Green Team https://thesustainablegreenteam.com/sgtm-blog/f/tony-raynor-founder-and-ceo-of-the-sustainable-green-team?blogcategory=SGTM+Leadership
SGTM
TrendTrade2016 TrendTrade2016 7 minutes ago
Exactly the same as RCAT and SPAI 3 for 3 in the drone intelligence sector
RCAT SPAI
navycmdr navycmdr 8 minutes ago
Share Price Forecast week 11/25 $fnma & $fmcc:

@FannieMae (FNMA): Given the positive housing market indicators and the anticipation around policy changes, FNMA shares are likely to experience a modest increase. Analysts might expect a 5% to 10% rise in share price this week, assuming
FMCC FNMA
sctts sctts 8 minutes ago
$$$ Today is the Day $$$$

$$$$ $FRX $$$$
FRX
tw0122 tw0122 8 minutes ago
WLDS $3.16 +'67%
WLDS
uranium-pinto-beans uranium-pinto-beans 11 minutes ago
EQT
EQT Corporation announces $3.5B joint venture with BXCI
EQT Corporation announced that it has entered into a definitive agreement with funds managed by Blackstone Credit & Insurance, or BXCI, to form a new midstream joint venture, or JV, consisting of EQT's ownership interest in
uranium-pinto-beans uranium-pinto-beans 12 minutes ago
EQT
EQT Corporation announces $3.5B joint venture with BXCI
EQT Corporation announced that it has entered into a definitive agreement with funds managed by Blackstone Credit & Insurance, or BXCI, to form a new midstream joint venture, or JV, consisting of EQT's ownership interest in
Zorch305 Zorch305 12 minutes ago
Last week of November coming at yah
RNVA
uranium-pinto-beans uranium-pinto-beans 12 minutes ago
goooooooood morning
elks elks 13 minutes ago
Getting there ducks in row. Low shares in public float. For only being. 00s.
SINC
mdb1 mdb1 13 minutes ago
Up $.05 in preMkt. Here comes the slow climb to $190s/$210s.
NVDA
Golden Cross Golden Cross 13 minutes ago
$ILLR CTB high at 118% ~ Prime_Short_Squeeze_Play

https://investorshub.advfn.com/uimage/uploads/2024/11/25/njkuictb.png
ILLR
cottonisking cottonisking 14 minutes ago
🥵🤑🥵I was having so much fun. Now everyone will be afraid of me and will not let me play with them anymore. 😂
LEHNQ
Golden Cross Golden Cross 14 minutes ago
$ILLR CTB high at 118% ~ Prime_Short_Squeeze_Play

https://investorshub.advfn.com/uimage/uploads/2024/11/25/njkuictb.png
ILLR
Truthsocial Truthsocial 16 minutes ago
Big Pharma down much more ...let's go RDGL

https://www.prageru.com/video/dr-marty-makary-on-eye-opening-discoveries-in-health-and-medicine

New FDA commissioner soon
RDGL
deri21 deri21 17 minutes ago
$NWBO $SHPH Featured Article
https://richardacavalli.wixsite.com/greenplanetmicrocaps/trillion-dollar-cancer-treatments
NWBO SHPH
Golden Cross Golden Cross 17 minutes ago
🚀 NEWS/Volume could trigger a MASSIVE short squeeze here! Most of new shares are still under 165-day lock-up. $ILLR is still on uptrend since post-merger low. 📈

$ILLR
ILLR
TrendTrade2016 TrendTrade2016 17 minutes ago
Weekly master class gapping
CDXS
Golden Cross Golden Cross 17 minutes ago
$ILLR Cost To Borrow still high at three figures here: 118%

https://investorshub.advfn.com/uimage/uploads/2024/11/25/njkuictb.png
ILLR

Your Recent History

NASDAQ
MURA
Mural Oncology
NASDAQ
ANNX
Annexon
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved